Clinical trials: Prostatic Disease
Robotic Radical Perineal Prostatectomy
Robotic Radical Perineal Prostatectomy Study
Radical perineal prostatectomy (RPP) was the first approach utilized for the removal of the entire prostate gland for prostate cancer.
- Trial name
- NCT04919057
- Testing
- GelPOINT®
- Where
- Hong Kong
- Sponsor
- Chinese University of Hong Kong
Cancer, Prostate Cancer
ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
A Phase 1/2 multicenter, dose determining, open-label study of ADXS31-142 monotherapy and a combination of ADXS31-142 and pembrolizumab (MK-3475) in participants with metastatic castration-resistant prostate cancer.
- Trial name
- NCT02325557
- Testing
- ADXS31-142, Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 50 people
- Sponsor
- Advaxis, Inc.
Prostate Cancer, Radiotherapy Side Effect
Prostate Reirradiation Toxicity Outcomes Feasibility Study
The RO-PIP trial aims to determine the feasibility of recruitment to a trial randomising patients to salvage ultra-hypofractionated external beam radiotherapy or high dose rate brachytherapy and provide prospective data on…
- Trial name
- RO-PIP (NCT05614700)
- Testing
- Brachytherapy, Sterotactic Body Radiotherapy
- Volunteers
- 60 people
- Sponsor
- University of Leeds
Benign Prostatic Hyperplasia (BPH)
HoLEP in Management of BPH Patients With Predominant Voiding vs Storage LUTS: A Comparative Retrospective Study
Comparison in outcomes of a minimally invasive surgical modality (Holmium Laser Enucleation of Prostate) in management of voiding versus storage lower urinary tract symptoms associated with Benign Prostatic Hyperplasia
- Trial name
- NCT04178811
- Testing
- Holmium Laser Enucleation of Prostate
- Where
- Egypt
- Volunteers
- 132 people
- Sponsor
- Assiut University
Primary Prevention of Prostate Cancer
Prostate Cancer Prevention Trial With Quercetin and Genistein
The aim of the randomized controlled double-blind crossover trial is to evaluate the effectiveness of two dietary supplements containing polyphenolic phytochemicals (isoflavonoid genistein and flavonoid quercetin) in comparison…
- Trial name
- QUERGEN (NCT01538316)
- Testing
- Quercetin supplement, Genistein supplement
- Where
- 2 sites in Germany
- Volunteers
- 60 people
- Sponsor
- University of Hohenheim
Prostatic Neoplasms, Lymphatic Metastasis
Prospective Validation of Pathology-based Artificial Intelligence Diagnostic Model for Lymph Node Metastasis in Prostate Cancer
The goal of this diagnostic test is to prospectively test the performance of pre-developed artificial intelligence (AI) diagnostic model for detecting pathological lymph node metastasis (LNM) of prostate cancer.
- Trial name
- NCT06253065
- Testing
- Artificial intelligence (AI)-based diagnostic model (developed)
- Where
- China
- Volunteers
- 225 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone
Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy
This phase I/II trial studies the best dose of M3814 when given together with radium-223 dichloride or with radium-223 dichloride and avelumab and to see how well they work in treating patients with castrate-resistant prostate…
- Conditions
- Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT04071236
- Testing
- Avelumab, Biospecimen Collection, Bone Scan
- Where
- 32 sites in United States
- Volunteers
- 90 people
- Sponsor
- National Cancer Institute (NCI)
Urinary Calculi, Benign Prostatic Hyperplasia
Flexiva Pulse Registry
To obtain post-market safety and efficacy data for FlexivaTM Pulse High Power Single-Use Laser Fibers during lithotripsy and soft tissue procedure of holmium laser enucleation of the prostate (HoLEP).
- Trial name
- NCT05027971
- Testing
- Flexiva Pulse High Power Single-Use Laser Fibers
- Where
- 4 sites in United States
- Volunteers
- 201 people
- Sponsor
- Boston Scientific Corporation
Prostate Cancer
Prostate Cancer Intervention Versus Observation Trial (PIVOT)
Radical prostatectomy provides potentially curative removal of the cancer. However, it subjects patients to the morbidity and mortality of the surgery and may be neither necessary nor effective.
- Trial name
- PIVOT (NCT00007644)
- Testing
- Radical prostatectomy
- Where
- 31 sites in United States
- Volunteers
- 731 people
- Sponsor
- VA Office of Research and Development
Prostate Cancer
Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer
Prostate cancer is the most common non-cutaneous cancer in men. Patients with recurrent or metastatic prostate cancer are treated with androgen-deprivation therapy, often termed castration therapy.
- Trial name
- NCT01620593
- Testing
- Metformin
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Prostate Cancer
Non-inferiority Trial Omitting Drainage After Robot-assisted Radical prostatectomY
This is a multicenter, prospective, randomized, controlled, open-label, assessor-blinded, non-inferiority trial evaluating whether pelvic drainage can be safely omitted after robot-assisted radical prostatectomy (RARP).
- Trial name
- POND-RARP (NCT07887321)
- Testing
- No Pelvic Drain Placement, Pelvic Drain Placement
- Where
- 3 sites in China
- Volunteers
- 400 people
- Sponsor
- Shanghai East Hospital
Prostate Adenocarcinoma, Radiotherapy; Complications
Twice High Dose External Beam Radiotherapy by Image-guided Tomotherapy for Organ-confined Prostate Cancer Treatment Emulating High Dose Radiation (HDR) Brachytherapy
Feasibility trial of twice high dose radiotherapy using Tomotherapy in patients with organ confined Prostate Cancer histologically proven.
- Conditions
- Prostate Adenocarcinoma, Radiotherapy; Complications, Tomotherapy
- Trial name
- THRIP (NCT03553212)
- Testing
- tomotherapy
- Where
- Italy
- Volunteers
- 2 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Prostate Cancer
Multiparametric MRI for Prostate Cancer Localization and Characterization: New Methods
The purpose of this study is to determine the ability of several new MRI techniques (MR elastography, dynamic contrast-enhanced MRI with gadofosveset, and oscillating gradient diffusion) to determine the location, size, and grade…
- Trial name
- NCT01761812
- Testing
- MRI with gadofosveset and MR elastography
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- Sunnybrook Health Sciences Centre
Benign Prostatic Hyperplasia
Analysis of Prostatic Arterial Embolization for Benign Prostatic Hyperplasia Using Embosphere Microspheres
Investigators hypothesis that arterial embolization of men with symptomatic BPH, analogous to uterine fibroid embolization for women, is safe and effective.
- Trial name
- NCT02679430
- Testing
- Prostate Arterial Embolization
- Where
- United States
- Sponsor
- Antonios Likourezos
Metastatic Castration-Resistant Prostate Cancer
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
This Phase 2 study will investigate the safety and clinical activity of vudalimab (XmAb20717) alone or in combination with standard of care anticancer therapies in patients with metastatic castration-resistant prostate cancer…
- Trial name
- NCT05005728
- Testing
- vudalimab + carboplatin + cabazitaxel, vudalimab + olaparib, vudalimab monotherapy
- Where
- 26 sites in United States
- Volunteers
- 72 people
- Sponsor
- Xencor, Inc.
Benign Prostatic Hyperplasia (BPH)
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With BPH
This clinical trial is designed as a randomized, placebo-controlled, single-blind, parallel design, multi-center, phase 2 clinical trial to evaluate the efficacy and safety of GV1001 in patients with benign prostatic hyperplasia.
- Trial name
- NCT02855892
- Testing
- GV1001
- Where
- 8 sites in South Korea
- Volunteers
- 161 people
- Sponsor
- GemVax & Kael
Prostate Cancer
To Compare the Safety and Pharmacokinetics of PT105 With PT105R in Healthy Postmenopausal Female Volunteers
The purpose of study is to compare the safety and pharmacokinetics of PT105 with PT105R in healthy postmenopausal female volunteers
- Trial name
- NCT04783636
- Testing
- leuprorelin acetate 3.75mg
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Peptron, Inc.
Prostate Cancer
Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer
The purpose of this study is to learn the long term efficacy and side effects associated with utilizing Stereotactic Body Radiation Therapy (SBRT) radiation for prostate cancer utilizing the Elekta Versa or Agility System.
- Trial name
- NCT03889119
- Testing
- Stereotactic Body Radiation Therapy (SBRT) radiation for prostate cancer utilizing the Elekta Versa or Agility System.
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Hoag Memorial Hospital Presbyterian
Metastatic Malignant Neoplasm in the Prostate Gland, Prostate Carcinoma
Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation
This exploratory study investigates how a new imaging technique called FAPI PET/CT can determine where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulates in normal and cancer tissues in patients with prostate cancer.
- Conditions
- Metastatic Malignant Neoplasm in the Prostate Gland, Prostate Carcinoma, Recurrent Prostate Carcinoma
- Trial name
- FAPI PET Prost (NCT04457232)
- Testing
- Computed Tomography, Gallium Ga 68 FAPi-46, Positron Emission Tomography
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer
Phase 1 Trial of PAN-301-1 (SNS-301) in Cancer Patients
This is a Phase I, open-label, parallel design study of PAN-301-1 (SNS-301), a HAAH directed nanoparticle vaccine, given intradermally in cohorts of patients with biochemically relapsed prostate cancer, using a fixed dose…
- Trial name
- NCT03120832
- Testing
- PAN-301-1
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Sensei Biotherapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.